Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Oct 31;22(1):282.
doi: 10.1186/s12931-021-01879-6.

Progressive fibrosing interstitial lung disease: prevalence and clinical outcome

Byoung Soo Kwon  1 , Jooae Choe  2 , Eun Jin Chae  2 , Hee Sang Hwang  3 , Yong-Gil Kim  4 , Jin Woo Song  5
Affiliations

Progressive fibrosing interstitial lung disease: prevalence and clinical outcome

Byoung Soo Kwon et al. Respir Res. .

Abstract

Background: The progressive fibrosing (PF) phenotype of interstitial lung disease (ILD) is characterised by worsening respiratory symptoms, lung function, and extent of fibrosis on high-resolution computed tomography. We aimed to investigate the prevalence and clinical outcomes of PF-ILD in a real-world cohort and assess the prognostic significance of the PF-ILD diagnostic criteria.

Methods: Clinical data of patients with fibrosing ILD other than idiopathic pulmonary fibrosis (IPF) consecutively diagnosed at a single centre were retrospectively reviewed. A PF phenotype was defined based on the criteria used in the INBUILD trial.

Results: The median follow-up duration was 62.7 months. Of the total of 396 patients, the mean age was 58.1 years, 39.9% were men, and rheumatoid arthritis-ILD was the most common (42.4%). A PF phenotype was identified in 135 patients (34.1%). The PF-ILD group showed lower forced vital capacity and total lung capacity (TLC) than the non-PF-ILD group. The PF-ILD group also showed poorer survival (median survival, 91.2 months vs. not reached; P < 0.001) than the non-PF-ILD group. In multivariable Cox analysis adjusted for age, DLCO, HRCT pattern, and specific diagnosis, PF phenotype was independent prognostic factor (hazard ratio, 3.053; P < 0.001) in patients with fibrosing ILD. Each criterion of PF-ILD showed similar survival outcomes.

Conclusions: Our results showed that approximately 34% of patients with non-IPF fibrosing ILD showed a progressive phenotype and a poor outcome similar to that of IPF, regardless of the diagnostic criteria used.

Keywords: Interstitial lung disease; Outcome; Phenotype; Prevalence; Progressive.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Study flow chart. ILD interstitial lung disease, IPF idiopathic pulmonary fibrosis, PF progressive fibrosing, iNSIP idiopathic nonspecific interstitial pneumonia, HP hypersensitivity pneumonitis
Fig. 2
Fig. 2
Prevalence of PF-ILD. PF progressive fibrosing, ILD interstitial lung disease, HP hypersensitivity pneumonitis, iNSIP idiopathic nonspecific interstitial pneumonia, RA rheumatoid arthritis, SSc systemic sclerosis, SJS SjÖgren syndrome
Fig. 3
Fig. 3
Comparison of survival curves between the PF-ILD and non-PF-ILD groups among patients with fibrosing ILD. PF progressive fibrosing, ILD interstitial lung disease
Fig. 4
Fig. 4
Comparison of survival curves in patients with PF-ILD according to PF-ILD diagnostic criteria. a Comparison of survival curves in patients with PF-ILD according to the diagnostic criteria used in this study. Criterion (i) a relative decline in FVC ≥ 10%; Criterion (ii) a relative decline in FVC of 5%–10% and worsening of respiratory symptoms or increased extent of fibrosis on HRCT; Criterion (iii) worsening of respiratory symptoms and increased extent of fibrosis on HRCT. b Comparison of survival curves in patients with PF-ILD according to the diagnostic criteria (INBUILD, Cottin et al., Behr et al., and George et al.)
See this image and copyright information in PMC

References

    1. Travis WD, Costabel U, Hansell DM, King TE, Jr, Lynch DA, Nicholson AG, Ryerson CJ, Ryu JH, Selman M, Wells AU, et al. An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013;188:733–748. doi: 10.1164/rccm.201308-1483ST. - DOI - PMC - PubMed
    1. Wijsenbeek M, Kreuter M, Olson A, Fischer A, Bendstrup E, Wells CD, Denton CP, Mounir B, Zouad-Lejour L, Quaresma M. Progressive fibrosing interstitial lung diseases: current practice in diagnosis and management. Curr Med Res Opin. 2019;35:2015–2024. doi: 10.1080/03007995.2019.1647040. - DOI - PubMed
    1. Wells AU, Brown KK, Flaherty KR, Kolb M, Thannickal Victor J. What's in a name? That which we call IPF, by any other name would act the same. Eur Respir J. 2018;51:1800692. doi: 10.1183/13993003.00692-2018. - DOI - PubMed
    1. Juge P-A, Lee JS, Ebstein E, Furukawa H, Dobrinskikh E, Gazal S, Kannengiesser C, Ottaviani S, Oka S, Tohma S, et al. MUC5B promoter variant and rheumatoid arthritis with interstitial lung disease. N Engl J Med. 2018;379:2209–2219. doi: 10.1056/NEJMoa1801562. - DOI - PMC - PubMed
    1. Ley B, Newton CA, Arnould I, Elicker BM, Henry TS, Vittinghoff E, Golden JA, Jones KD, Batra K, Torrealba J, et al. The MUC5B promoter polymorphism and telomere length in patients with chronic hypersensitivity pneumonitis: an observational cohort-control study. Lancet Respir Med. 2017;5:639–647. doi: 10.1016/S2213-2600(17)30216-3. - DOI - PMC - PubMed